Highly shifted LIPOCEST agents based on the encapsulation of neutral polynuclear paramagnetic shift reagents.
Department of Chemisry IFM and Molecular Imaging Center, University of Torino, Via P. Giuria 7, I-10125, Torino, Italy.Chemical Communications (Impact Factor: 6.38). 03/2008; DOI: 10.1039/b715383j
ABSTRACT Improved LIPOCEST MRI contrast agents with highly shifted intraliposomal water protons were prepared by entrapping neutral polynuclear Tm(III)-based paramagnetic shift reagents in phospholipidic vesicles.
- [Show abstract] [Hide abstract]
ABSTRACT: Pulsed Low Intensity Non-Focused Ultrasound (LINFU) was used to trigger the release from liposomes of the clinically approved Magnetic Resonance Imaging (MRI) agent Gadoteridol. The extent of the release was monitored by relaxometric measurements upon changing both ultrasound stimulus (power, application times and mode, duty cycle values) and physico-chemical variables of the theranostic agent (liposomes size, shape, chemical composition, and concentration of the encapsulated agent). The release was not heat-mediated, but promoted by mechanical interactions between the acoustic radiation waves and the soft nanovesicles. The application of pulsed LINFU led to a controlled release detectable by both Nuclear Magnetic Resonance (NMR) relaxometry and MRI. Such promising observations were followed by an in vivo proof-of-concept study on a syngeneic B16 melanoma mouse model. The obtained results demonstrated the great potential of LINFU for designing MRI-guided protocols aimed at visualizing the release of drugs from liposomal carriers. This study could bring to the development of a new therapeutic for personalized medicine.Journal of Medical Imaging and Health Informatics 09/2013; Vol. 3:356–366. · 0.64 Impact Factor
- Gait & Posture - GAIT POSTURE. 01/1996; 4(2):180-180.
- [Show abstract] [Hide abstract]
ABSTRACT: Targeted therapy is becoming an increasingly important component in the treatment of cancer. How to accurately monitor targeted therapy has been crucial in clinical practice. The traditional approach to monitor treatment through imaging has relied on assessing the change of tumor size by refined World Health Organization criteria, or more recently, by the Response Evaluation Criteria in Solid Tumors. However, these criteria, which are based on the change of tumor size, show some limitations for evaluating targeted therapy. Currently, genetic alterations are identified with prognostic as well as predictive potential concerning the use of molecularly targeted drugs. Conversely, considering the limitations of invasiveness and the issue of expression heterogeneity, molecular imaging is better able to assay in vivo biologic processes noninvasively and quantitatively, and has been a particularly attractive tool for monitoring treatment in clinical cancer practice. This review focuses on the applications of different kinds of molecular imaging including positron emission tomography-, magnetic resonance imaging-, ultrasonography-, and computed tomography-based imaging strategies on monitoring targeted therapy. In addition, the key challenges of molecular imaging are addressed to successfully translate these promising techniques in the future.International Journal of Nanomedicine 01/2013; 8:3703-3713. · 4.20 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.